China Outlines Ambitious Roadmap To Clean Up Clinical Data Quality
This article was originally published in PharmAsia News
Reeling from a series of scandals involving clinical trial data, China FDA has put forth a comprehensive plan to tackle the issue, stressing urgency and the need to meet global standards. While many challenges remain, the agency says it will work closely with industry stakeholders to strengthen the “quality mentality.”
You may also be interested in...
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.